Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

DSpace/Manakin Repository

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Citable link to this page

 

 
Title: Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
Author: Momeny, Majid; Moghaddaskho, Farima; Gortany, Narges K.; Yousefi, Hassan; Sabourinejad, Zahra; Zarrinrad, Ghazaleh; Mirshahvaladi, Shahab; Eyvani, Haniyeh; Barghi, Farinaz; Ahmadinia, Leila; Ghazi-Khansari, Mahmoud; Dehpour, Ahmad R.; Amanpour, Saeid; Tavangar, Seyyed M.; Dardaei, Leila; Emami, Amir H.; Alimoghaddam, Kamran; Ghavamzadeh, Ardeshir; Ghaffari, Seyed H.

Note: Order does not necessarily reflect citation order of authors.

Citation: Momeny, M., F. Moghaddaskho, N. K. Gortany, H. Yousefi, Z. Sabourinejad, G. Zarrinrad, S. Mirshahvaladi, et al. 2017. “Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.” Scientific Reports 7 (1): 44075. doi:10.1038/srep44075. http://dx.doi.org/10.1038/srep44075.
Full Text & Related Files:
Abstract: Glioblastoma (GBM) remains one of the most fatal human malignancies due to its high angiogenic and infiltrative capacities. Even with optimal therapy including surgery, radiotherapy and temozolomide, it is essentially incurable. GBM is among the most neovascularised neoplasms and its malignant progression associates with striking neovascularisation, evidenced by vasoproliferation and endothelial cell hyperplasia. Targeting the pro-angiogenic pathways is therefore a promising anti-glioma strategy. Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells through a G2/M cell cycle arrest via inhibition of polo-like kinase 1 (PLK1) signalling pathway and down-modulation of Aurora kinases A and B, cyclin B1 and CDC25C. Moreover, tivozanib decreased adhesive potential of these cells through reduction of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Tivozanib diminished GBM cell invasion through impairing the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2). Combination of tivozanib with EGFR small molecule inhibitor gefitinib synergistically increased sensitivity to gefitinib. Altogether, these findings suggest that VEGFR blockade by tivozanib has potential anti-glioma effects in vitro. Further in vivo studies are warranted to explore the anti-tumour activity of tivozanib in combinatorial approaches in GBM.
Published Version: doi:10.1038/srep44075
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347040/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071965
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters